Factors associated with hepatitis B vaccine series completion in a randomized trial for injection drug users reached through syringe exchange programs in three US cities by unknown
Bowman et al. BMC Public Health 2014, 14:820
http://www.biomedcentral.com/1471-2458/14/820RESEARCH ARTICLE Open AccessFactors associated with hepatitis B vaccine series
completion in a randomized trial for injection
drug users reached through syringe exchange
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Background: Hepatitis B virus (HBV) is a vaccine preventable infection yet vaccination rates are low among
injection drug users (IDUs) despite the high risk of infection and longstanding recommendations to promote
vaccination. We sought to improve vaccination rates by reaching IDUs through syringe exchange programs (SEPs)
in three U.S. cities.
Methods: IDUs were randomized in a trial comparing the standard HBV vaccination schedule (0, 1, and 6 months)
to an accelerated schedule (0, 1, and 2 months) and participation data were analyzed to identify determinants of
completion of the three-dose vaccine series. Independent variables explored included sociodemographics, injection
and syringe access behaviors, assessment of health beliefs, HBV-associated knowledge, and personal health status.
Results: Covariates associated with completion of the three-dose vaccine series were accelerated vaccine schedule
(aOR 1.92, 95% CI 1.34, 2.58, p = <0.001), older age (aOR 1.05, 95% CI 1.03, 1.07, p = <0.001), and poorer self-rated
health score (aOR 1.26, 95% CI 1.05, 1.5, p = 0.02). Completion was less likely for those getting syringes from SEP
customers than for SEP customers (OR 0.33, 95% CI 0.19, 0.58, p = <0.001).
Conclusions: SEPs should offer hepatitis vaccination in a manner that minimizes time between first and last visits
by accelerating the dosing schedule. Public health interventions should target younger, less healthy, and non-SEP
customer participants. Other health interventions at SEPs may benefit from similar approaches that reach out
beyond regular SEP customers.
Keywords: Hepatitis B, Vaccination, Syringe exchange programs, Injection drug usersBackground
The availability since 1982 of a safe and effective vaccine
against the hepatitis B virus (HBV) has dramatically re-
duced the annual incidence of acute HBV infections
from an estimated 13.8 cases per 100,000 population in
1987 to an estimated 1.5 cases per 100,000 population in
2007 [1,2]. Nevertheless, one risk group with continued
high incidence is injection drug users (IDUs) [3-5].
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many remain unvaccinated [5-8]. Studies of HBV vaccine
programs delivered either by referral to health clinics or
on-site at syringe exchange programs (SEPs) have con-
cluded that offering convenient locations and modest
financial incentives, including contingency management
approaches, greatly increased vaccine uptake and comple-
tion of the three-dose series [4,9-12]. A third approach
to improving completion of the series is accelerating the
schedule to shorten the usual six-month schedule. An
accelerated version of the vaccine series administered
over the course of two months has been shown to be
similarly effective [13,14].al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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uptake among active IDUs we conducted the Hepatitis
Vaccine Study (HVS) that included all three compo-
nents: using syringe exchanges to find eligible high risk
individuals, paying them to participate, and comparing
the standard six-month and an accelerated two-month
HBV vaccination schedule. The comparison was con-
ducted as a randomized trial in at SEPs in three cities –
Hartford and Bridgeport in Connecticut and Chicago in
Illinois. Participants were offered a modest monetary in-
centive for each dose received. A previous analysis con-
cerned the cost-effectiveness of the two strategies [15].
Here we report our analysis of factors associated with
non-completion of the vaccine series. We hypothesized
that the longer interval of the standard regimen, less fre-
quent use of the SEP to obtain syringes, low hepatitis B
knowledge, and low self-efficacy would be associated
with non-completion of the vaccine series.
Methods
The research protocol was approved by the IRBs at Yale
University, DePaul University (Chicago) and the Hispanic
Health Council (Hartford). Participants received $10-15
for each study visit that they completed (i.e., up to $75 for
the five visits).
Study sample and procedures
An in-depth description of the study sample and proce-
dures has been published elsewhere [15,16]. Participants
were enrolled between May 2003 and March 2006 at
SEP locations in the three cities. Individuals were eligible
to receive the vaccine if they could demonstrate evi-
dence of having injected within the past 30 days
(injection stigmata), were 18 years of age or older, were
screened for and found susceptible to HBV, and were
deemed able to provide informed consent. Oral consent
for screening and subsequent participation based on
HBV vaccination and infection status was obtained orally
prior to screening.
To determine eligibility for vaccination, participants
were screened by serological testing for antibodies to
core and surface antigens (HBcAb and HBsAb, respec-
tively) and for surface antigen (HBsAg). Individuals who
tested negative for all three tests were informed that
they were susceptible to HBV infection and invited to
receive vaccination through the study. Individuals who
tested HBcAb-positive, regardless of the test results for
HBsAb were informed that they had been previously
infected. Individuals who tested HBsAb-positive but
negative on the other tests were informed that they had
been previously successfully vaccinated. Individuals who
tested HBsAg-positive, regardless of either of the other
two HBV results, were informed that they were likely to
be actively infected, instructed when they returned fortheir results to seek medical care, and advised on how to
avoid transmitting the virus to others.
Those whose serologic tests results indicated that they
were susceptible to HBV infection were administered
the first vaccine dose when they returned for their test
results and then instructed to return for the second dose
one month later. A random numbers assignment log,
maintained at each study site, was used to assign par-
ticipants to either the standard (0, 1, and 6 months) or
accelerated (0, 1, and 2 months) schedule at the Dose 2
visit. All participants were invited to return for a final
visit seven months after their first dose to assess acquisi-
tion of protective immunity, and in Chicago a fourth
dose was given to those in the accelerated arm. The re-
cruitment, intervention, and analysis scheme is shown in
Figure 1.
Data collection
The outcome of interest was administration of the final
vaccine dose (Dose 3) among those receiving Dose 1. A
set of covariates was included to test our hypotheses and
identify confounders. These included treatment group,
SEP usage variables, city of enrolment, sociodemogra-
phic variables, current health status variables, injection
practices, and history of either engaging in or receiving
commercial sex work services. Hepatitis knowledge and
psychosocial factors were also assessed. The hepatitis
knowledge instrument was an adaptation of the National
Institute on Drug Abuse Risk Behavior Assessment ques-
tionnaire and included 22 questions using a True/False/
Don’t Know response format to assess knowledge of
routes of infection, disease detection and treatment, and
prevention options [17,18]. The psychosocial instrument,
developed specifically for this study and grounded in
Protection Motivation Theory, contained 21 items that
assessed the six constructs in the theoretical model
[19,20]. These included respondents’ perceptions about
(1) personal vulnerability to HBV infection, (2) disease se-
verity for HBV infection, (3) response efficacy of specific
prevention behaviors (e.g., using SEPs, refusing to share
injection equipment) in reducing risk of HBV infection,
(4) self-efficacy for engaging in specific prevention behav-
iors, (5) social peers’ approval of the respondent engaging
in HBV risk reduction behaviors (i.e., social outcome ex-
pectancy), and (6) the importance of social approval from
their peers (i.e., social outcome value). Items were phrased
as an “I- statements” and used a 5-point Likert response
format ranging from Strongly Agree to Strongly Disagree.
The number of items included in each sub-scale ranged
from one (vulnerability and severity subscales) to seven (re-
sponse efficacy) items. Inter-item correlations (Cronbach’s
alpha) for the multiple-item subscales were calculated and
ranged from 0.62 to 0.86. Data obtained from these items
were converted to z-scores, and the mean score for each
Figure 1 CONSORT schematic for the standard and accelerated arms of the HVS study.
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cluded concerning motives for participation that included
remaining healthy, protecting the health of others, partici-
pating in research, and receiving compensation.
Analytic methods
Statistical analyses were conducted using SAS version
9.1. Logistic regression was used to calculate bivariate
associations between all co-variates and the outcome.
Covariates that were significantly associated with vaccine
completion at the p ≤ 0.10 level in the bivariate analyses
were subsequently entered into a multivariate logisticregression model with backwards elimination of any co-
variate that did not remain significant at the p < 0.05
level or did not change other coefficients by >10%.
We also explored several areas of potential collinearity.
To test the hypothesis that those earning more money
were more likely to have had a recent medical visit and
less likely to use SEPs [21,22], chi-square tests were used
to test for associations between income and doctor visits
during the past year and income and SEP utilization.
The laws governing syringe exchange varied with there
being no limit to the number of syringes that could be
received at each visit in Chicago in contrast to a cap of
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in Hartford and Bridgeport. Therefore, to test if there
was an interaction between participants’ main source of
syringes and their city of enrollment, an interaction term
was created and entered into a multivariate logistic re-
gression including the interaction term and main effects
with receiving Dose 3 as the outcome.
Results and discussion
Of the 860 individuals who screened susceptible to HBV
infection, 595 (69.2%) returned for the Dose 1 visit and
were enrolled in the vaccine study. A total of 460 partici-
pants (77.3% of those receiving Dose 1) returned for
their second dose. Of the 271 randomized to the stan-
dard group, 141 (52.0% of Dose 1 recipients) returned
for Dose 3, and 120 (44.4% of Dose 1 recipients) re-
turned for the follow-up visit. Among the 324 rando-
mized to the accelerated arm, 206 (63.6% of Dose 1
recipients) returned for Dose 3, and 116 (35.8% of Dose
1 recipients) returned for the follow-up visit.
Table 1 presents the results of the bivariate analyses.
As hypothesized, completion of the vaccine series was
significantly higher for participants in the accelerated
arm versus the standard arm, for those receiving most of
their syringes directly from the SEP where they were en-
rolled in the study as opposed to another source, and for
direct SEP customers than for people whose main source
of syringes in the past 30 days had been secondary ex-
change (i.e., a direct SEP customer provided the par-
ticipant with SEP syringes). In addition, completion rates
were higher among those offered vaccination at the
Chicago SEP, among non-Hispanic Blacks versus His-
panics, among women versus men, among those un-
employed versus employed, and among those of older age,
and poorer self-rated health status. The results did not
support the hypotheses that greater HBV knowledge or
self-efficacy to be vaccinated would be significantly associ-
ated with completion. In addition, perceived motivations
for participating were not significantly associated with
completion of the vaccination series. Further analysis re-
vealed no interactions between city and main source of
syringes over the past three months, between income and
most recent medical visit within the past year, or between
income and SEP utilization (data not shown).
All covariates that were significant at the p ≤ 0.10 level
in the bivariate analyses were entered into a multivariate
model (Table 2). Four variables remained significantly
associated with completion of the vaccine series such
that those who completed the series were more likely:
(1) to have been randomized to the accelerated treat-
ment group, (2) to be direct SEP customers rather than
to report using secondary exchange as their main source
of syringes in the past thirty days, (3) to be older, and
(4) having poorer self-rated health status.Methods
This analysis, designed to compare completion rates be-
tween two dosing schedules, was constructed on the hy-
pothesis that completion rates would be higher among
the accelerated group. A second manuscript comparing
efficacy between those randomized to the accelerated
versus the standard schedule is in preparation. As an-
ticipated, vaccination completion was significantly more
likely among participants in the accelerated treatment
group, suggesting that shortening the vaccine schedule
reduces the risk of encountering barriers to participation
common among IDUs, which can include incarceration
or competing health care and personal needs.
Low rates of completion of the three-dose HBV vac-
cine series have previously been documented among
IDUs especially in, but not limited to, the United States
[9,23-25]. Accelerated HBV vaccine dosing schedules
that have been implemented among hard-to-reach po-
pulations including active IDUs have been shown to
increase completion rates [8,26-29]. However, none of
these prior studies has used SEPs as the access point
for identifying and vaccinating active injectors. In our
present study, despite offering financial incentives for
vaccination at SEPs, only 58% of Dose 1 recipients com-
pleted the vaccine series. However, several studies have
established a consensus that paying individuals do in-
crease vaccination completion rates in drug injecting
populations [10,30,31].
There has been discussion regarding whether or not a
booster dose is necessary for the accelerated HBV vac-
cine series. Although benefits of a booster dose for the
accelerated HBV vaccine schedule have been suggested,
several studies have concluded that booster doses are
neither necessary nor is maintenance of an antibody
level ≥10 mIU/mL essential for protection because an
anamnestic response has been detected up to 22 years
post-vaccination [32-34]. Further research would be ne-
cessary to evaluate the feasibility of offering a 12-month
booster dose at SEPs. Although this might not seem a
priority in light of the above findings, the lower success
rate for vaccination among people who inject drugs
suggests that a booster might be appropriate in this
population [24,35-39].
Completion was slightly more likely among older par-
ticipants, consistent with earlier findings of low vac-
cination rates among young injectors and among younger
people in general [8,11,40]. Thus, special attention should
be paid to recruiting and retaining younger participants,
especially since they are less likely to have already been ex-
posed to and infected with HBV (albeit increasingly more
likely in the future to have been vaccinated against HBV
infection in early childhood). Multifaceted interventions,
targeting youth within their community deserve further
consideration. A review of the literature on services and
Table 1 Unadjusted correlates of dose 3 completion
N* uOR 95% CI p-value
Accelerated treatment group 595 1.61 1.16 2.24 0.01
City 595
Chicago Reference
Hartford 0.75 0.46 1.22 0.25
Bridgeport 0.48 0.24 0.93 0.03
Race 588
Non-Hispanic Black/African American Reference
White 0.74 0.49 1.13 0.15
Hispanic 0.63 0.43 0.94 0.02
Excluded Native American/Alaskan Native, Other, Refused (n = 7)
Women 594 1.45 1.00 2.11 0.05
Age (continuous, range 18–68) 595 1.05 1.03 1.07 <.01
Education 581
Less Than high school Reference
High school or graduate equivalency degree 0.94 0.63 1.39 0.74
Some College or College graduate 1.15 0.76 1.75 0.51
Excluded missing other (14) and vocation schools (11)
Employment (Full- or part-time) 578 0.66 0.44 1.01 0.05
Average monthly income
$0-300 Reference
$301-556 0.87 0.52 1.45 0.58
$557-1,000 1.10 0.70 1.73 0.68
$1,001-9,000 0.76 0.47 1.23 0.26
Not homeless 577 0.93 0.66 1.31 0.68
Excluded missing (n = 14), and don’t know (n = 4)
Pay for housing 582 1.43 1.03 1.99 0.04
Self-reported health status (Likert 1 = excellent, 5 = poor) 578 1.21 1.02 1.42 0.03
Excluded missing (13) and don’t know (4)
Told by health care worker HCV pos 576 0.97 0.59 1.60 0.90
Excluded missing (15) and don’t know/unsure (4)
Doctors visit during past year 582 1.06 0.74 1.51 0.80
Customer of local syringe exchange 539 0.98 0.64 1.49 0.91
Main source of syringes, prior 30 days 558
SEP direct Reference
Pharmacy 0.45 0.19 1.05 0.06
SEP customer 0.37 0.22 0.64 <0.01
Diabetic, someone else, at place you shoot 0.79 0.47 1.34 0.38
Excluded missing (37)
Most syringes from this exchange, past 3 months 462 1.59 1.07 2.37 0.02
EVER referred by SEP to healthcare/drug tx/social service 575 1.29 0.28 2.00 0.26
Excluded missing (17) don’t know (3)
Average # of shots from a syringe (range 1–75) 557 0.98 0.93 1.02 0.31
Total injections, prior 30 days (range 1–540) 521 1.00 0.99 1.00 0.84
Excluded does not apply (n = 25)
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Table 1 Unadjusted correlates of dose 3 completion (Continued)
Used a needle someone else had used at least, prior 30 days 553 1.73 0.90 3.33 0.10
Someone paid you w/ drugs or money for sex 580 1.21 0.81 1.80 0.36
You paid someone with drugs or money for sex 575 0.83 0.55 1.25 0.38
Language of interview 582
English Reference
Spanish 0.57 0.30 1.10 0.09
Language spoken most often 578
English Reference
Spanish 0.76 0.45 1.27 0.30
Excluded missing and other (n = 3)
Hepatitis Knowledge 585 2.78 0.45 17.10 0.27
Vulnerability 581 1.01 0.85 1.19 0.94
Severity 581 1.10 0.93 1.30 0.25
Response efficacy 580 1.01 0.85 1.19 0.94
Self-efficacy 581 0.93 0.79 1.10 0.39
Social outcome expectancy 580 1.04 0.88 1.23 0.64
Social outcome value 581 1.05 0.89 1.24 0.57
*The number of people answering each question is included, numbers may not equal 595 due to missing data.
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that interventions addressing the varied and intercon-
nected needs of youth are more successful than those tar-
geting one problem at a time [41,42]. Further research is
needed to specifically understand barriers to vaccine pro-
gram completion among young injectors.
Participants with a poorer self-rated health score were
more likely to complete the vaccine series. This runs
counter to expectations from previous work that found
competing needs served as a barrier to health care ac-
quisition and preventive health care, particularly among
vulnerable populations including homeless adults and
IDUs [43-45]. This may, instead, be one example of the
potential for collinearity in the variables in our dataset.
Older individuals were more likely to report poorerTable 2 Multivariate logistic regression of correlates
associated with dose 3 completion (N = 430*)
aOR 95% CI p-value
Accelerated Treatment Group 1.92 1.34 2.58 <0.001
Age (continuous) 1.05 1.03 1.07 <0.001
Less healthy (Likert Scale 1–5) 1.26 1.05 1.5 0.01
Main source of syringes past 3 months
Direct from SEP Reference
Direct from pharmacy 0.43 0.179 1.04 0.60
From SEP customer 0.33 0.19 0.58 <0.001
Other 0.68 0.39 1.18 0.17
*165 observations were excluded due to missing values for the outcome or
explanatory variables.health (data not shown) and were also more likely to
complete the vaccine series.
Compared to direct SEP customers, a significantly lower
completion rate was observed among people who engaged
in secondary exchange. The benefit of providing health
services at SEPs has been repeatedly demonstrated
[3,9,12,23,46,47], but this advantage may be of limited
benefit to non-customers. Our findings suggest that
recruitment of non-SEP customers should draw on peer
networks in addition to more traditional recruitment stra-
tegies (e.g., outreach, posted fliers). SEP customers who
distribute SEP syringes to non-customers should be
encouraged to promote participation through their own
social networks, word of mouth, or easy-to-distribute pro-
motional cards. The underlying reasons that some IDUs
do not go directly to SEPs were not assessed within the
current study. Further research is needed to identify bar-
riers to SEP utilization and alternative methods for tar-
geting this hidden population of IDUs.
This study has a number of limitations. First, par-
ticipants were predominantly direct or indirect SEP cus-
tomers, so the findings have limited generalizability to the
full IDU population in these communities. Second, as with
any study that relies on self-reported behavioral data, this
evaluation may be influenced by self-report and recall bias.
Third, recruitment methods were intended to simulate
what would be realistic and feasible for a typical SEP with
limited resources and staffing to implement a vaccination
intervention; the recruitment strategy may have resulted
in a non-random sampling that may have introduced un-
measured bias into the study population. Fourth, lack of
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as sources of income, a full medical history, and the pre-
cise nature of social relationships limited a full assessment
of competing subsistence or health needs. Finally, enrol-
ment was slow. It took three years to recruit sufficient
participants to power the analysis. We have previously re-
ported that an improved study design would have involved
getting rid of the two-week waiting period for test result
to identify those eligible for vaccination and giving the
first dose of vaccine at enrolment [15]. This approach was
also found to be most cost-effective.
Conclusions
The findings from this evaluation lead us to conclude that
IDUs can be encouraged to participate in preventative
health promotion efforts through SEPs, although services
at SEPs are most likely to reach only the direct SEP cus-
tomers. Since most non-completers obtained their syrin-
ges from other SEP customers, drawing on peer networks
to undertake a peer-driven intervention and maintain con-
tact with non-customers may promote completion of the
vaccine series [48-51]. Specific attention is also required
to encourage completion among younger and/or healthier
participants to obtain and complete HBV vaccination. Our
findings furthermore suggest that SEPs offering hepatitis
vaccination should consider minimizing the time between
first and last visits, one strategy for which is offering the
first HBV vaccination at the screening visit [15]. Finally,
our results suggest that paying individuals to get vac-
cinated is only one of several programmatic requirements
to insure maximum coverage.
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